Research programme: anticancer therapies - Moleculin Biotech/University of Texas M. D. Anderson Cancer Center

Drug Profile

Research programme: anticancer therapies - Moleculin Biotech/University of Texas M. D. Anderson Cancer Center

Alternative Names: 2-DG prodrug; CP2005; Degrasyns; Tyrphostins; WP 1066; WP 1122; WP 1234; WP1106; WP1129; WP1130

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Moleculin
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Bcr-abl tyrosine kinase inhibitors; Glycolysis inhibitors; Janus kinase-2 inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Nov 2017 MD Anderson files an IND, along with responses to the US FDA requests for additional information, for WP 1066 in Brain cancer
  • 11 Oct 2017 Moleculin Biotech expands its agreement with the University of Bergen to study WP 1066 and its unique ability to increase immune system response to cancer and suppression of tumor cell proliferation and survival
  • 08 Sep 2017 Moleculin Biotech enters into an agreement with the University of Bergen to study WP 1122 in combination with bevacizumab
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top